Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients

被引:38
|
作者
Nuytemans, Karen [1 ,2 ,3 ]
Rademakers, Rosa [1 ,2 ,3 ]
Theuns, Jessie [1 ,2 ,3 ]
Pals, Philippe [2 ,3 ,4 ]
Engelborghs, Sebastiaan [3 ,5 ]
Pickut, Barbara [6 ]
de Pooter, Tim [1 ,2 ,3 ]
Peeters, Karin [1 ,2 ,3 ]
Mattheijssens, Maria [1 ,2 ,3 ]
Van den Broeck, Marleen [1 ,2 ,3 ]
Cras, Patrick [3 ,4 ]
De Deyn, Peter Paul [3 ,5 ,6 ]
van Broeckhoven, Christine [1 ,2 ,3 ]
机构
[1] Univ Antwer, Neurodegenerat Brain Dis Grp, Dept Mol Genet, CDE,VIB, B-2610 Antwerp, Belgium
[2] Inst Born Bunge, Neurogenet Lab, Antwerp, Belgium
[3] Univ Antwerp, Born Bunge Fdn, Neurobiol Lab, B-2020 Antwerp, Belgium
[4] Univ Antwerp Hosp, Div Neurol, Antwerp, Belgium
[5] Inst Born Bunge, Lab Neurochem & Behav, Antwerp, Belgium
[6] ZNA Middleheim Gen Hosp, Div Neurol, Antwerp, Belgium
关键词
Parkinson's disease; LRRK2; p.R1441C founder mutation;
D O I
10.1038/sj.ejhg.5201986
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We determined the prevalence of mutations in two major functional domains of the leucine-rich repeat kinase 2 gene (LRRK2) in Belgian Parkinson's disease (PD) patients (N = 304) of which 18.1% were familial PD patients. Ten patients were heterozygous for five different missense mutations (3.29%) of whom six carried the same mutation p. R1441C (1.97%). All six p. R1441C carriers were familial PD patients explaining 10.7% of familial PD in the Belgian patient group. Moreover, they shared a common disease haplotype of 21 consecutive markers in a region of 438 kb, suggesting that they are distant descendants of a single common ancestor. Clinically, p. R1441C carriers had typical levodopa-responsive parkinsonism with tremor as the most common presenting feature. Their age at onset was highly variable and ranged from 39 to 73 years, suggesting the influence of modifying factors. The remaining four patients were heterozygous each for a novel missense mutation located in the Roc or kinase domain. The pathogenic nature of these mutations remains to be determined, though we have genetic evidence that at least some represent rare but benign variants rather than causal mutations. The latter observation indicates that prudence is needed in diagnostic testing of LRRK2 in PD patients. Functional data should underlie a conclusion on the pathogenic nature of some mutations that have not been conclusively linked to disease.
引用
收藏
页码:471 / 479
页数:9
相关论文
共 50 条
  • [1] Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients
    Karen Nuytemans
    Rosa Rademakers
    Jessie Theuns
    Philippe Pals
    Sebastiaan Engelborghs
    Barbara Pickut
    Tim de Pooter
    Karin Peeters
    Maria Mattheijssens
    Marleen Van den Broeck
    Patrick Cras
    Peter Paul De Deyn
    Christine van Broeckhoven
    European Journal of Human Genetics, 2008, 16 : 471 - 479
  • [2] The Incidence of Mutation on the Leucine-rich Repeat Kinase 2 Gene in Patients with Parkinson's Disease in Slovakia
    Kracunova, K.
    Kovacovicova, M.
    Baldovic, M.
    Valkovic, P.
    Kadasi, L'
    Benetin, J.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2011, 74 (04) : 443 - 445
  • [3] Leucine-rich repeat kinase 2 and Parkinson's disease
    Kang, Un-Beom
    Marto, Jarrod A.
    PROTEOMICS, 2017, 17 (1-2)
  • [4] Parkinson disease and leucine-rich repeat kinase 2 gene mutation: abridged secondary publication
    Ho, S. L.
    Ho, P. W. L.
    Siu, D. C. W.
    HONG KONG MEDICAL JOURNAL, 2020, 26 (06) : 22 - 26
  • [5] A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia
    Illarioshkin, S. N.
    Shadrina, M. I.
    Slominsky, P. A.
    Bespalova, E. V.
    Zagorovskaya, T. B.
    Bagyeva, G. Kh.
    Markova, E. D.
    Limborska, S. A.
    Ivanova-Smolenskaya, I. A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 (04) : 413 - 417
  • [6] Targeting leucine-rich repeat kinase 2 in Parkinson's disease
    Chan, Sharon L.
    Angeles, Dario C.
    Tan, Eng-King
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (12) : 1471 - 1482
  • [7] Leucine-rich repeat kinase 2: Relevance to Parkinson's disease
    Guo, Luxuan
    Wang, Wen
    Chen, Shu G.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2006, 38 (09): : 1469 - 1475
  • [8] G2019S Mutation of the Leucine-Rich Repeat Kinase 2 Gene in a Cohort of Egyptian Patients with Parkinson's Disease
    Hashad, Doaa I.
    Abou-Zeid, Abla A.
    Achmawy, Ghada A.
    Allah, Horeya M. O. Saad
    Saad, Marwa A.
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2011, 15 (12) : 861 - 866
  • [9] Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease
    Elliott, David A.
    Kim, Woojin S.
    Gorissen, Sarsha
    Halliday, Glenda M.
    Kwok, John B. J.
    MOVEMENT DISORDERS, 2012, 27 (08) : 1004 - 1011
  • [10] The heterozygous R1441C mutation of leucine-rich repeat kinase 2 gene in a Chinese patient with Parkinson disease: A five-year follow-up and literatures review
    Peng, Fang
    Sun, Yi-Min
    Chen, Chen
    Luo, Su-Shan
    Li, Da-Ke
    Wang, Yi-Xuan
    Yang, Ke
    Liu, Feng-Tao
    Zuo, Chuan-Tao
    Ding, Zheng-Tong
    An, Yu
    wu, Jian-Jun
    Wang, Jian
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 373 : 23 - 26